BGBIO.OL实时信号 | 通过Getagraph.com最大化利润

出售 346 min ago

@ NOK0.149

发出时间: 29 Apr 2024 @ 19:53

回报率: -0.13%

上一信号: Apr 29 - 17:53

上一信号: 购买

回报率: 0.27 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:25):
Our systems believe the stock currently is undervalued by 0.67% compare to its pairs and should correct upwards.

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
今日成交量	26.59M
平均成交量	43.06M
市值	399.54M
EPS	NOK0 ( 2024-02-15 )
下一个收益日期	( NOK-0.0200 ) 2024-05-23
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.270
ATR14	NOK0.00800 (5.41%)

相关性 (AI algo v.1.1b): Undervalued: 0.67% NOK0.149 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.23 (neutral)

短: 0.00 (neutral)

Signal:(37) Neutral

BerGenBio ASA 相关性

10 最正相关
PLT.OL	0.937
ELIMP.OL	0.935
KMCP.OL	0.931
TRVX.OL	0.925
ELABS.OL	0.908
ABG.OL	0.895
AKER.OL	0.893
VOW.OL	0.892
SADG.OL	0.891
EFUEL.OL	0.884

10 最负相关
AYFIE.OL	-0.95
ATEA.OL	-0.929
TECH.OL	-0.886
ELK.OL	-0.885
BAKKA.OL	-0.882
BWO.OL	-0.877
PEXIP.OL	-0.871
BOUV.OL	-0.865
GOD.OL	-0.864
SMOP.OL	-0.862

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

BerGenBio ASA 相关性 - 货币/商品

0.00
( neutral )

BerGenBio ASA 财务报表

Annual	2022
营收:	NOK389 000
毛利润:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2022
营收:	NOK389 000
毛利润:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2021
营收:	NOK774 000
毛利润:	NOK0.00 (0.00 %)
EPS:	NOK-3.52

FY	2020
营收:	NOK601 000
毛利润:	NOK0.00 (0.00 %)
EPS:	NOK-3.43

Financial Reports:

No articles found.

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.